CARdiovascular Outcome study of LINAgliptin versus glimepiride in patients with T2D trial.
作者信息
Nath Baishali, Suvarna Viraj Ramesh
机构信息
Department of Medical, Eris Lifesciences Limited, Ahmedabad, Gujarat, India.
出版信息
Perspect Clin Res. 2020 Jan-Mar;11(1):44-46. doi: 10.4103/picr.PICR_157_19. Epub 2020 Jan 31.
Abstract
摘要
相似文献
1
CARdiovascular Outcome study of LINAgliptin versus glimepiride in patients with T2D trial.利奈格列汀与格列美脲治疗2型糖尿病患者的心血管结局研究
Perspect Clin Res. 2020 Jan-Mar;11(1):44-46. doi: 10.4103/picr.PICR_157_19. Epub 2020 Jan 31.
2
Linagliptin versus glimepiride add-on for the long-term treatment of Type 2 diabetes mellitus.利格列汀与格列美脲联合用药用于2型糖尿病的长期治疗
Expert Rev Endocrinol Metab. 2013 Jul;8(4):345-349. doi: 10.1586/17446651.2013.811849.
3
Rationale and design of the CAROLINA® - cognition substudy: a randomised controlled trial on cognitive outcomes of linagliptin versus glimepiride in patients with type 2 diabetes mellitus.CAROLINA®认知子研究的原理与设计：一项关于利格列汀与格列美脲对2型糖尿病患者认知结局影响的随机对照试验
BMC Neurol. 2018 Jan 15;18(1):7. doi: 10.1186/s12883-018-1014-7.
4
Linagliptin monotherapy in type 2 diabetes patients for whom metformin is inappropriate: an 18-week randomized, double-blind, placebo-controlled phase III trial with a 34-week active-controlled extension.利那格列汀单药治疗二甲双胍不适用的2型糖尿病患者：一项为期18周的随机、双盲、安慰剂对照III期试验及为期34周的活性药物对照延长期试验
Diabetes Obes Metab. 2012 Dec;14(12):1145-54. doi: 10.1111/dom.12011. Epub 2012 Oct 1.
5
Effect of linagliptin compared with glimepiride on postprandial glucose metabolism, islet cell function and vascular function parameters in patients with type 2 diabetes mellitus receiving ongoing metformin treatment.与格列美脲相比，利格列汀对正在接受二甲双胍治疗的2型糖尿病患者餐后葡萄糖代谢、胰岛细胞功能和血管功能参数的影响。
Diabetes Metab Res Rev. 2014 Oct;30(7):582-9. doi: 10.1002/dmrr.2525.
6
Linagliptin in patients with type 2 diabetes and cardiovascular and/or renal disease: results from a cardiovascular and renal outcomes trial.利拉鲁肽治疗 2 型糖尿病伴心血管和/或肾脏疾病患者的疗效：一项心血管和肾脏结局试验的结果。
Postgrad Med. 2020 May;132(4):314-319. doi: 10.1080/00325481.2020.1742524. Epub 2020 Mar 20.
7
The combination of linagliptin, metformin and lifestyle modification to prevent type 2 diabetes (PRELLIM). A randomized clinical trial.利拉利汀、二甲双胍联合生活方式改变预防 2 型糖尿病（PRELLIM）。一项随机临床试验。
Metabolism. 2020 Mar;104:154054. doi: 10.1016/j.metabol.2019.154054. Epub 2019 Dec 28.
8
Linagliptin enhances neural stem cell proliferation after stroke in type 2 diabetic mice.利那格列汀可增强2型糖尿病小鼠中风后的神经干细胞增殖。
Regul Pept. 2014 May;190-191:25-31. doi: 10.1016/j.regpep.2014.05.001. Epub 2014 May 10.
9
Cardiovascular safety of linagliptin in type 2 diabetes: a comprehensive patient-level pooled analysis of prospectively adjudicated cardiovascular events.利格列汀在2型糖尿病中的心血管安全性：一项对前瞻性判定的心血管事件进行的全面患者水平汇总分析。
Cardiovasc Diabetol. 2015 May 21;14:57. doi: 10.1186/s12933-015-0215-2.
10
Cardiovascular safety of linagliptin compared with other oral glucose-lowering agents in patients with type 2 diabetes: A sequential monitoring programme in routine care.在 2 型糖尿病患者中，与其他口服降糖药相比，利拉利汀的心血管安全性：常规护理中的连续监测计划。
Diabetes Obes Metab. 2019 Aug;21(8):1824-1836. doi: 10.1111/dom.13735. Epub 2019 May 1.
引用本文的文献
1
Pathophysiology and Advances in the Therapy of Cardiomyopathy in Patients with Diabetes Mellitus.糖尿病心肌病的病理生理学及治疗进展。
Int J Mol Sci. 2024 May 5;25(9):5027. doi: 10.3390/ijms25095027.
2
Management of diabesity: Current concepts.糖尿病肥胖症的管理：当前概念
World J Diabetes. 2023 Apr 15;14(4):396-411. doi: 10.4239/wjd.v14.i4.396.
3
Antihyperglycemic Medications and Cardiovascular Risk Reduction.降糖药物与心血管风险降低
Eur Endocrinol. 2017 Aug;13(2):86-90. doi: 10.17925/EE.2017.13.02.86. Epub 2017 Aug 22.
4
Assessment of the cardiovascular safety of saxagliptin in patients with type 2 diabetes mellitus: pooled analysis of 20 clinical trials.2型糖尿病患者中沙格列汀心血管安全性评估：20项临床试验的汇总分析
Cardiovasc Diabetol. 2014 Feb 4;13:33. doi: 10.1186/1475-2840-13-33.
本文引用的文献
1
Effect of Linagliptin vs Placebo on Major Cardiovascular Events in Adults With Type 2 Diabetes and High Cardiovascular and Renal Risk: The CARMELINA Randomized Clinical Trial.利拉利汀对比安慰剂对伴有高心血管和肾脏风险的 2 型糖尿病成人患者主要心血管事件的影响：CARMELINA 随机临床试验。
JAMA. 2019 Jan 1;321(1):69-79. doi: 10.1001/jama.2018.18269.
2
Sulfonylureas: Assets in the past, present and future.磺脲类药物：过去、现在及未来的价值。
Indian J Endocrinol Metab. 2015 May-Jun;19(3):314-6. doi: 10.4103/2230-8210.149925.
3
Design and baseline characteristics of the CARdiovascular Outcome Trial of LINAgliptin Versus Glimepiride in Type 2 Diabetes (CAROLINA®).利格列汀与格列美脲在2型糖尿病中的心血管结局试验（CAROLINA®）的设计与基线特征
Diab Vasc Dis Res. 2015 May;12(3):164-74. doi: 10.1177/1479164115570301. Epub 2015 Mar 15.
4
The UGDP controversy: thirty-four years of contentious ambiguity laid to rest.UGDP争议：34年的争议性模糊尘埃落定。
Perspect Biol Med. 2004 Autumn;47(4):564-74. doi: 10.1353/pbm.2004.0071.
5
Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group.罗非昔布与萘普生对类风湿关节炎患者上消化道毒性的比较。VIGOR研究组。
N Engl J Med. 2000 Nov 23;343(21):1520-8, 2 p following 1528. doi: 10.1056/NEJM200011233432103.
Zotero 插件